Year: 2021

Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA Verrica is engaging with the FDA on next steps toward potential approval of VP-102 for the treatment of molluscum contagiosum WEST CHESTER, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2021. “We are pleased that the issues identified at the CMO unrelated to VP-102 have been successfully resolved, enabling us to move toward approval,” said Ted White, Verrica’s President and Chief Executive Officer. “We remain confident in VP-102’s commercial potential. There...

Record Results Driven by 122% Increase in Year-Over-Year Fee Paying Assets Under Management DALLAS, Nov. 12, 2021 (GLOBE NEWSWIRE) —  P10, Inc. (NYSE: PX), a leading private markets solutions provider, today reported financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights:Fee Paying Assets Under Management: $16.3 billion as of the end of the quarter, a 122% increase year-over-year Revenue: $38.1 million for the quarter, a 148% increase year-over-year Net Income: $4.1 million for the quarter, a $4 million increase year-over-year Net Income attributable to P10: $3.6 million for the quarter, a $3.7 million increase year-over-year Adjusted EBITDA: $21.8 million for the quarter, a 148% increase year-over-year Adjusted Net Income: $16.2 million for the quarter, a 146% increase year-over-year Earnings...

— Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds — — Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications — DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments. “Humacyte has made great strides advancing our bioengineered tissue platform to create novel human acellular tissues and organs. This quarter was marked with significant corporate progress, including the closing of our...

Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated by year end 2021 and first half 2022 Announced collaboration with Yale University Department of Immunobiology to explore use of AIM INJ in regard to regulation of Type 1 DiabetesGAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the third quarter of 2021. “We had another strong quarter as characterized by our continued progress developing the AIM technology platform,” said Scott Carmer, Chief Executive Officer. “Our primary focus remains on completing...

CRANBURY, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule therapies designed to activate p53 function, today reported financial results for the third quarter ended September 30, 2021 and provided corporate highlights. “We made important progress in the third quarter of 2021 as we advanced the clinical development of our lead candidate, PC14586, an investigational small molecule p53 Y220C reactivator, and strengthened our corporate foundation to ensure that we have the talent and resources in place to support our future success,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “Our ongoing Phase 1/2 trial of PC14586 is progressing well, with twelve sites at leading oncology centers,...

Alan Fuhrman appointed interim President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing Clinical data readouts anticipated in 2022 CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced third quarter 2021 financial results and provided a business update. “We are excited about the future of vidutolimod as a potential novel treatment for multiple tumor types, including melanoma and head and neck cancer. We continue to advance our clinical trials towards potential data readouts in 2022,” said Alan Fuhrman, interim President and Chief Executive Officer...